Publications
63
Citations
3,004
Est. group size
~5
Recurring co-author estimate
Active years
31
Publishing since 1995
Typically publishes in teams of ~9 · 5% small-team papers (≤3 authors) · across 22 venues
- Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research · 2025
- Development of an Artificial Intelligence–Based Model to Precisely Measure Body Surface Area in Psoriasis
Journal of Investigative Dermatology · 2025
- Demographic characteristics and disease severity associated with IgA/IgG deposition patterns in autoimmune bullous diseases: a cohort study based on a registry database
Frontiers in Immunology · 2025
- QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).
Journal of Clinical Oncology · 2025
- Table S2 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Figure S1 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Table S1 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Figure S2 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Data from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Table S3 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Figure S3 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Figure S6 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Figure S4 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Figure S5 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025
- Autoimmune Bullous Disease Combined With Acquired Hemophilia A: A Systematic Review and Case Analysis
The Journal of Dermatology · 2025
- Clinical Lymphoma Myeloma & Leukemia×6
- Acta Pharmaceutica Sinica B×3
- Clinical Cancer Research×3
- ACS Applied Materials & Interfaces×3
- Biomaterials×2
- Abdullah Khan
Medicine · The Ohio State University
- Jing Christine Ye
Medicine · University of Michigan
- David F. Keren
Medicine · University of Michigan
- Attaya Suvannasankha
Medicine · Indiana University
- Enze Liu
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile